SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, and Pakistan's The Searle Company Limited (PSX: SEARL, ...
Zoledronate infusion preserves BMD gains after denosumab discontinuation for women with osteoporosis
Please provide your email address to receive an email when new articles are posted on . Discontinuation of denosumab is associated with a rapid return to pretreatment BMD levels and an increased risk ...
THOUSAND OAKS, Calif., May 20, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...
Amgen is celebrating the news that regulators in the USA have given a second green light to the biotech's key compound denosumab. Amgen is celebrating the news that regulators in the USA have given a ...
"Today's approval of XGEVA illustrates what is possible when scientific innovation, commitment and investment come together to advance medicine," said Kevin Sharer, chairman and chief executive ...
MONTREAL, QUEBEC — Two recent studies — a case series and a secondary analysis of a large phase 3 trial — shed more light on the rare increased risk of vertebral fractures after discontinuing ...
THOUSAND OAKS, Calif., May 8, 2023 /PRNewswire/ -- Amgen (AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback